Is alverine citrate safe for use in a pregnant woman in her second trimester?

Alverine Citrate Safety in Second Trimester Pregnancy

Alverine citrate should be avoided during the second trimester of pregnancy due to insufficient safety data, despite one study showing no pain reduction benefit in early pregnancy medical abortion. There are no guidelines, FDA labeling, or adequate human pregnancy data to support its safe use during any trimester.

Evidence Assessment

Lack of Safety Data

The only human pregnancy data available comes from a single study examining alverine for pain control during first-trimester medical abortion (≤8 weeks gestation), which found it ineffective at reducing pain 1. Critically, this study provides no safety outcomes for the fetus or pregnancy continuation, and does not address second-trimester use.

No Regulatory Guidance

The FDA drug label for alverine citrate 2 is essentially a placeholder document for "Anticoagulant Sodium Citrate Solution" and does not contain prescribing information, pregnancy category, or safety data for alverine citrate as a spasmolytic medication. This absence of regulatory guidance is a significant red flag.

Pharmacokinetic Concerns

Recent pharmacokinetic data reveals that alverine undergoes extensive metabolism, with the active metabolite 4-hydroxy alverine accounting for 94% of circulating drug-related compounds 3. The study also demonstrates high pharmacokinetic variability in the general population, with hydroxylation being particularly susceptible to outlying performance. This unpredictable metabolism raises concerns about fetal exposure, especially since:

• Placental transfer characteristics are unknown
• Fetal metabolic capacity differs from adults
• Variable maternal metabolism could lead to unpredictable fetal drug levels

Clinical Decision Framework

When Alverine Might Be Considered (Theoretical)

The indication matters: alverine is used for gastrointestinal spasms, irritable bowel syndrome, and dysmenorrhea 3. However:

For GI symptoms in pregnancy:

• First-line: Non-pharmacologic approaches (dietary modification, hydration)
• Safe alternatives exist: Calcium carbonate for reflux, osmotic laxatives for constipation 4
• Metoclopramide is established as safe for nausea 5

For abdominal cramping/spasm:

• Acetaminophen (with judicious use given recent safety concerns) 4, 6
• Hyoscine butylbromide has more pregnancy data than alverine

Critical Pitfalls to Avoid

1. Do not assume safety based on widespread use - alverine's common prescription does not equate to proven pregnancy safety
2. Do not extrapolate from the abortion study - showing no benefit in pain control during pregnancy termination tells us nothing about safety in ongoing pregnancy
3. Do not rely on "probably safe" reasoning - the high metabolic variability and lack of placental transfer data make this assumption dangerous

Practical Recommendation

If a pregnant patient in her second trimester presents requiring treatment for conditions where alverine might be considered:

1. Identify the specific symptom (GI spasm, IBS, cramping)
2. Use established safe alternatives with pregnancy data:
   • GI symptoms: H2 antihistamines, proton pump inhibitors 4
   • Cramping: Acetaminophen (short-term only) 4, 6
3. If already taking alverine: Discontinue and transition to safer alternative
4. Document the lack of safety data if patient insists on continuation

The absence of evidence is not evidence of safety, particularly when safer alternatives with established pregnancy profiles exist.